ClinicalTrials.gg

Program

SPGL008

A development code.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms, led by 3SBio.

Furthest: phase 2, since Feb 5, 20263 company-led studies, 3 open or runningNext primary completion: Nov 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio33 open or runningphase 2since Feb 5, 2026Jun 17, 2025Nov 2027phase 2 · NCT07874984

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 17, 2025First study: phase 1 study in Advanced Malignant TumorsFirst studyNCT07038005 · 96 planned · China
  2. Feb 5, 2026Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsPhase 2 reachedNCT07445308 · 120 planned
  3. Sep 20, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07874984 · 220 planned

Ahead

  1. Nov 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07874984
  2. Nov 21, 2028Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT07445308

TargetBeta

IL15 →IL15RA →read by rule
“SPGL008 is a dual-functional molecule that combines an anti-B7-H3 monoclonal antibody with IL-15Rα sushi / IL-15.”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
nogapendekin alfa inbakiceptruleImmunityBiophase 345

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07874984Carcinoma, Non-Small-Cell Lung2Not yet recruitingNov 2027220
NCT07445308Non-Muscle Invasive Bladder Neoplasms2Not yet recruitingNov 21, 2028120
NCT07038005Advanced Malignant Tumors · China1RecruitingSep 22, 202696

How it is read

Names in the registry

  • “SPGL008”, 3 entries

Codes read as this program: SPGL008.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.